浙江大学博士学位论文CML酪氨酸激酶抑制剂分子靶向药物及异基因造血干细胞移植分层治疗研究姓名:***学位级别:博士专业:内科学(血液病学)指导教师:**20120518浙江大学博士学位论文中文摘要CML酪氨酸激酶抑制剂分子靶向药物及异基因造血干细胞移植分层治疗研究浙江大学医学部博士研究生导师内科学(血液病学)罗依黄河教授中文...
2005/08/17[CML] 10 year anniversaryjhgraham2001 2005/08/17[CML] High CK/CPK in Blood Work while on Gleevec?doshirakesh 2005/08/17[CML] Re: [CMLHope] Good test results!Rob 2005/08/17Re: [CML] Recent Cml DiagnosisRob 2005/08/17[CML] Re: Gleevac at a cheaper rateRob ...
imatinib doses had higher and faster response rates in the first year of treatment, but by 42 months the high- and low-dose arms showed similar rates of major molecular response (MMR) and no differences in event-free survival (EFS), progression-free survival (PFS), or overall survival (...
Following the chronic phase, an accelerated phase, sometimes called transformation can occur, with the development of a rapidly increasing number of blasts in the peripheral circulation. Once this occurs, survival is normally between 2 and 6 months. How is Chronic Myeloid Leukaemia Treated? The exac...
efficacy with an improvement in the safety profile. In this randomized, open-label, phase 3 trial, 233 patients with chronic-phase CML previously treated with 2 or more TKIs were evaluated. After 24 weeks, the MMR rate was 25.5% vs 13.2% for asciminib and bosutinib, respectively.15,16 ...
After the introduction of tyrosine kinase inhibitors (TKIs), the annual rate of progression from CML-CP to AP or BP dramatically decreased to 1–1.5% from more than 20% [1, 2]. However, the prognosis for adult patients with de novo or secondary CML-BP remains poor; median survival is ...
The International Randomized Study of Interferon and STI571 (IRIS) trial found an estimated cumulative com- plete cytogenetic response rate (CCyR) and overall survival of 87% and 89%, respectively, among 553 patients who received first-line imatinib for five years[4]. Despite the impressive ...
Five-year progression-free survival (PFS) and overall survival (OS) rates were similar across treatment arms (PFS: 85% [dasatinib], 86% [imatinib]; OS: 91% [dasatinib], 90% [imatinib]). A higher proportion of pts on dasatinib achieved BCR-ABL ≤10% at 3 months (84%) compared with...
survival prolongation, likely because of their potent efficacy and the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy. All four TKIs are equivalent if the aim of therapy is to improve survival. In younger patients with high‐...
factor.129,137 These data not only reinforce the importance of BCR-ABL1 in the post-transcriptional control of gene expres- sion,139 but also suggest a new function for miRNAs as functional regulators of RNA-binding proteins involved in the control of malignant cell growth, survival and ...